Is the PFS benefit sufficient to adopt up front acalabrutinib plus BR for all patients with MCL?
Given no OS benefit, are there certain subgroups of patients for whom you most strongly consider concurrent treatment vs using drugs in sequence?
Community PollStarted
Which factors most impact your decision to choose acala-BR over alternative frontline MCL regimens?
15 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Fox Chase Cancer Center
Answered on
In my opinion, PFS is not sufficient to adopt BR-acala as a universal treatment, but this can be an important treatment option for many patients. I would offer the BR-acala combo in patients who value maximizing duration of treatment response, recognizing this is a continuous regimen. On the other h...
Join for free or sign in to see the full answer
Mednet Member
Hematology · Fred Hutch Cancer Center
Answered on
As above, the magnitude of benefit is significant, but not "massive" (HR 0.73, 27% reduction in disease progression or death); and long-term BTK can mean a very long duration of immunosuppressive therapy without a break for these patients. I therefore prefer to target this approach to higher-risk pa...
Join for free or sign in to see the full answer